» Articles » PMID: 26355158

IFN-γ Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation Response

Overview
Journal J Immunol
Date 2015 Sep 11
PMID 26355158
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The priming of macrophages with IFN-γ prior to TLR stimulation results in enhanced and prolonged inflammatory cytokine production. In this study, we demonstrate that, following TLR stimulation, macrophages upregulate the adenosine 2b receptor (A2bR) to enhance their sensitivity to immunosuppressive extracellular adenosine. This upregulation of A2bR leads to the induction of macrophages with an immunoregulatory phenotype and the downregulation of inflammation. IFN-γ priming of macrophages selectively prevents the induction of the A2bR in macrophages to mitigate sensitivity to adenosine and to prevent this regulatory transition. IFN-γ-mediated A2bR blockade leads to a prolonged production of TNF-α and IL-12 in response to TLR ligation. The pharmacologic inhibition or the genetic deletion of the A2bR results in a hyperinflammatory response to TLR ligation, similar to IFN-γ treatment of macrophages. Conversely, the overexpression of A2bR on macrophages blunts the IFN-γ effects and promotes the development of immunoregulatory macrophages. Thus, we propose a novel mechanism whereby IFN-γ contributes to host defense by desensitizing macrophages to the immunoregulatory effects of adenosine. This mechanism overcomes the transient nature of TLR activation, and prolongs the antimicrobial state of the classically activated macrophage. This study may offer promising new targets to improve the clinical outcome of inflammatory diseases in which macrophage activation is dysregulated.

Citing Articles

Neoantigen mRNA vaccines and AA receptor antagonism: A strategy to enhance T cell immunity.

Imani S, Jabbarzadeh Kaboli P, Babaeizad A, Maghsoudloo M Hum Vaccin Immunother. 2025; 21(1):2458936.

PMID: 39882781 PMC: 11784654. DOI: 10.1080/21645515.2025.2458936.


Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy.

Yang L, Zhang Y, Yang L Cancer Biol Med. 2024; 21(11).

PMID: 39629670 PMC: 11667779. DOI: 10.20892/j.issn.2095-3941.2024.0228.


Unlocking the adenosine receptor mechanism of the tumour immune microenvironment.

Han Y, Dong C, Hu M, Wang X, Wang G Front Immunol. 2024; 15:1434118.

PMID: 38994361 PMC: 11236561. DOI: 10.3389/fimmu.2024.1434118.


A adenosine receptor signaling and regulation.

Gao Z, Haddad M, Jacobson K Purinergic Signal. 2024; .

PMID: 38833181 DOI: 10.1007/s11302-024-10025-y.


The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy.

Kang C, Liu L, Wu C, Li L, Jia X, Xie W Front Immunol. 2023; 14:1111369.

PMID: 36911717 PMC: 9995374. DOI: 10.3389/fimmu.2023.1111369.


References
1.
Kong T, Westerman K, Faigle M, Eltzschig H, Colgan S . HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J. 2006; 20(13):2242-50. DOI: 10.1096/fj.06-6419com. View

2.
Edwards J, Zhang X, Frauwirth K, Mosser D . Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006; 80(6):1298-307. PMC: 2642590. DOI: 10.1189/jlb.0406249. View

3.
St Hilaire C, Yang D, Schreiber B, Ravid K . B-Myb regulates the A(2B) adenosine receptor in vascular smooth muscle cells. J Cell Biochem. 2007; 103(6):1962-74. PMC: 3303598. DOI: 10.1002/jcb.21586. View

4.
Koupenova M, Ravid K . Adenosine, adenosine receptors and their role in glucose homeostasis and lipid metabolism. J Cell Physiol. 2013; . PMC: 3849123. DOI: 10.1002/jcp.24352. View

5.
St Hilaire C, Koupenova M, Carroll S, Smith B, Ravid K . TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun. 2008; 375(3):292-6. PMC: 2583397. DOI: 10.1016/j.bbrc.2008.07.059. View